Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06995677 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
A Phase 2 study of FGFR3 Gene Mutation and FGFR3 Gene Alteration, sponsored by Tyra Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT06995677 is a Phase 2 study of FGFR3 Gene Mutation and FGFR3 Gene Alteration that is actively recruiting participants, run by Tyra Biosciences. The registered enrollment target is 90 participants, below the 143-participant average among 3 other FGFR3 Gene Mutation trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06995677, a Phase 2 study of FGFR3 Gene Mutation and FGFR3 Gene Alteration, is actively recruiting participants, sponsored by Tyra Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
Conditions Studied
Interventions
- DRUG TYRA-300 60mg
- DRUG TYRA-300 50mg
- DRUG TYRA-300 Dose TBD
Study Locations (20)
California
- Tri Valley Urology - Murrieta - Murrieta
- Om Research LLC - San Diego
Illinois
- Associated Urological Specialists - Chicago Ridge
- Duly Health and Care - Lisle
New York
- Memorial Sloan Kettering Cancer Center - Sidney Kimmel Center for Prostate and Urologic Cancers - New York
- The Bronx Veterans Medical Research Foundation, Inc. - The Bronx
Pennsylvania
- MidLantic Urology - Bala-Cynwyd
- Keystone Urology Specialists - Lancaster
South Carolina
- Carolina Urologic Research Center - Myrtle Beach
- Lowcounty Urology Clinics, P.A. - North Charleston
Texas
- Baylor College of Medicine - Houston
- Urology San Antonio - San Antonio
Alabama
- Urology Centers of Alabama - Homewood
Arkansas
- Arkansas Urology - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-06-27 |
| Est. Completion | 2028-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06995677
The ClinicalTrials.gov registry entry for NCT06995677 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 143-participant average among 3 other FGFR3 Gene Mutation trials with a reported enrollment target (37% lower). The listed sponsor is Tyra Biosciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with FGFR3 Gene Mutation appearing as the primary indexed condition, and to 3 interventions - of which TYRA-300 60mg is the first listed.
NCT06995677 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT06995677 about?
NCT06995677 is a clinical study titled "Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer". Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
What is the current status of trial NCT06995677?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2025-06-27. Estimated completion is 2028-09.
What conditions does trial NCT06995677 study?
This clinical trial studies the following conditions: FGFR3 Gene Mutation, FGFR3 Gene Alteration, FGFR Gene Amplification, FGFR Gene Alterations, Low-grade NMIBC.
What interventions are being tested in trial NCT06995677?
The interventions under investigation include: TYRA-300 60mg (DRUG), TYRA-300 50mg (DRUG), TYRA-300 Dose TBD (DRUG).
Who is sponsoring clinical trial NCT06995677?
This trial is sponsored by Tyra Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06995677 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for FGFR3 Gene Mutation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
RECRUITING · Phase 1
-
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.